Dapu Biotechnology
PrivateLast Round
Series B
Extension
Jun 15, 2026
Total Funding Raised
$36.23M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Dapu Biotechnology operates in Healthcare & Life Sciences and is based in Jiaxing. Its latest recorded funding round was a Series B Extension round in June 2026.
Dapu Biotechnology is a biotechnology company that develops high-throughput droplet microfluidic technology and life science solutions for drug discovery and precision medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Pharma Supply Chain
Business Model
B2B
Customer Profile
Hardware Sales, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dapu Biotechnology Comparables
Compare Dapu Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Changzhou Smart-Lifesciences Biotechnology Co., Ltd. | 89% | |
| Wuxi Galak Chromatography Technology Co., Ltd. | 88% | |
| Suzhou Nano-Micro Technology Co., Ltd. | 81% |
For institutional investors. Book with your work email.
Dapu Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jun 15, 2026 | ||||
| Series B | Jan 4, 2024 | ||||
| Strategic | Sep 30, 2022 | ||||
| Series A | Aug 29, 2021 | ||||
| Early Funding | Aug 29, 2021 | ||||
Angel | Mar 26, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Dapu Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 上海浦东创业投资有限公司 | Series B Extension |
| DT Capital Partners | Series A, Early Funding |
| Hiway Capital | Series B Extension |
| Zhuopu Investment | Series B |
| Luxin Venture Capital Group Co., Ltd. | Series B |
| 深圳市南山战略新兴产业投资有限公司 | Series B Extension |
| Huaxin Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased to 14, 93% of headcount.
- Aug 29, 2026
Grew 25% QoQ, from 12 to 15 employees.
For institutional investors. Book with your work email.
Dapu Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Dapu Biotechnology's valuation, stock price, and market status.
Is Dapu Biotechnology a public or private company?
Dapu Biotechnology is a private company.
What is the current stock price of Dapu Biotechnology?
Dapu Biotechnology is a private company, so its shares have no public market price. Caplight tracks Dapu Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dapu Biotechnology worth (valuation)?
Valuation information for Dapu Biotechnology is not publicly available.
Can I buy Dapu Biotechnology stock?
Dapu Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dapu Biotechnology's last funding round?
Dapu Biotechnology's most recent funding round was Series B Extension on June 15, 2026.
Who are the main investors in Dapu Biotechnology?
Key investors in Dapu Biotechnology include 上海浦东创业投资有限公司, DT Capital Partners, Hiway Capital, Zhuopu Investment, Luxin Venture Capital Group Co., Ltd..
Will Dapu Biotechnology IPO soon?
No public IPO plans have been announced for Dapu Biotechnology.
How can I track Dapu Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Dapu Biotechnology's shares on secondary markets.